| 481 | Humans (MeSH) |
| 323 | Netherlands (epidemiology) |
| 258 | Netherlands (MeSH) |
| 228 | Female (MeSH) |
| 218 | Male (MeSH) |
| 201 | Influenza, Human (epidemiology) |
| 166 | Middle Aged (MeSH) |
| 164 | Influenza, Human (prevention & control) |
| 163 | Animals (MeSH) |
| 159 | Adult (MeSH) |
| 152 | Aged (MeSH) |
| 103 | Adolescent (MeSH) |
| 91 | Influenza in Birds (epidemiology) |
| 85 | Child, Preschool (MeSH) |
| 84 | Child (MeSH) |
| 81 | Infant (MeSH) |
| 77 | Influenza Vaccines (administration & dosage) |
| 74 | Influenza, Human (virology) |
| 66 | Aged, 80 and over (MeSH) |
| 60 | Seasons (MeSH) |
| 60 | Influenza in Birds (virology) |
| 59 | Young Adult (MeSH) |
| 56 | Disease Outbreaks (MeSH) |
| 55 | Surveys and Questionnaires (MeSH) |
| 53 | Incidence (MeSH) |
| 52 | Disease Outbreaks (veterinary) |
| 51 | Influenza A virus (isolation & purification) |
| 50 | Risk Factors (MeSH) |
| 48 | Influenza in Birds (transmission) |
| 46 | Poultry (MeSH) |
| 42 | Infant, Newborn (MeSH) |
| 41 | Influenza, Human (mortality) |
| 40 | Vaccination (statistics & numerical data) |
| 39 | Disease Outbreaks (prevention & control) |
| 34 | Retrospective Studies (MeSH) |
| 34 | Influenza Vaccines (immunology) |
| 34 | Influenza Vaccines (MeSH) |
| 31 | Influenza A virus (pathogenicity) |
| 31 | Influenza A virus (immunology) |
| 30 | Influenza in Birds (prevention & control) |
| 29 | Influenza A Virus, H1N1 Subtype (MeSH) |
| 28 | Influenza, Human (immunology) |
| 28 | Influenza Vaccines (therapeutic use) |
| 27 | Influenza, Human (transmission) |
| 27 | Influenza, Human (drug therapy) |
| 26 | Poultry Diseases (epidemiology) |
| 26 | Population Surveillance (MeSH) |
| 26 | Influenza, Human (diagnosis) |
| 26 | Birds (MeSH) |
| 26 | Antiviral Agents (therapeutic use) |
| 25 | Chickens (MeSH) |
| 25 | Age Factors (MeSH) |
| 24 | Vaccination (MeSH) |
| 24 | Influenza Vaccines (adverse effects) |
| 24 | Antibodies, Viral (blood) |
| 23 | Sentinel Surveillance (MeSH) |
| 23 | Respiratory Tract Infections (epidemiology) |
| 23 | Prospective Studies (MeSH) |
| 23 | Influenza, Human (complications) |
| 23 | Cross-Sectional Studies (MeSH) |
| 23 | Cost-Benefit Analysis (MeSH) |
| 22 | Cohort Studies (MeSH) |
| 21 | Prevalence (MeSH) |
| 21 | Influenza A virus (classification) |
| 21 | Influenza A Virus, H1N1 Subtype (immunology) |
| 20 | Time Factors (MeSH) |
| 20 | Influenza A virus (genetics) |
| 20 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
| 19 | Swine (MeSH) |
| 19 | Health Knowledge, Attitudes, Practice (MeSH) |
| 18 | Poultry Diseases (virology) |
| 18 | Hospitalization (statistics & numerical data) |
| 18 | Hemagglutination Inhibition Tests (MeSH) |
| 16 | Risk Assessment (MeSH) |
| 16 | Orthomyxoviridae (isolation & purification) |
| 16 | Odds Ratio (MeSH) |
| 16 | Influenza B virus (isolation & purification) |
| 15 | Pregnancy (MeSH) |
| 15 | Population Surveillance (methods) |
| 15 | Pandemics (MeSH) |
| 15 | Influenza B virus (immunology) |
| 15 | Influenza A virus (MeSH) |
| 15 | Attitude of Health Personnel (MeSH) |
| 14 | Orthomyxoviridae Infections (virology) |
| 14 | Internet (MeSH) |
| 13 | Treatment Outcome (MeSH) |
| 13 | Sensitivity and Specificity (MeSH) |
| 13 | Regression Analysis (MeSH) |
| 13 | Practice Guidelines as Topic (MeSH) |
| 13 | Phylogeny (MeSH) |
| 13 | Pandemics (prevention & control) |
| 13 | Oseltamivir (therapeutic use) |
| 13 | Mortality (MeSH) |
| 13 | Models, Biological (MeSH) |
| 13 | Influenza A Virus, H7N7 Subtype (MeSH) |
| 13 | Disease Outbreaks (statistics & numerical data) |
| 13 | Cause of Death (MeSH) |
| 13 | Age Distribution (MeSH) |
| 12 | Risk (MeSH) |
| 12 | Respiratory Tract Infections (virology) |
| 12 | Public Health (MeSH) |
| 12 | Nursing Homes (MeSH) |
| 12 | Influenza, Human (economics) |
| 12 | Influenza in Birds (diagnosis) |
| 12 | Health Personnel (MeSH) |
| 12 | Family Practice (MeSH) |
| 12 | Case-Control Studies (MeSH) |
| 12 | Animal Husbandry (MeSH) |
| 11 | Vaccination (psychology) |
| 11 | Vaccination (economics) |
| 11 | United States (MeSH) |
| 11 | United Kingdom (epidemiology) |
| 11 | Seroepidemiologic Studies (MeSH) |
| 11 | Orthomyxoviridae Infections (epidemiology) |
| 11 | Models, Theoretical (MeSH) |
| 11 | Models, Statistical (MeSH) |
| 11 | Logistic Models (MeSH) |
| 11 | Influenza in Birds (pathology) |
| 11 | Immunization Programs (MeSH) |
| 11 | Chickens (virology) |
| 11 | Animal Migration (MeSH) |
| 10 | Zoonoses (MeSH) |
| 10 | Sex Distribution (MeSH) |
| 10 | Influenza, Human (psychology) |
| 10 | Influenza, Human (microbiology) |
| 10 | Influenza in Birds (mortality) |
| 10 | Influenza Vaccines (economics) |
| 10 | Germany (epidemiology) |
| 10 | Cost of Illness (MeSH) |
| 10 | Birds (virology) |
| 9 | Severity of Illness Index (MeSH) |
| 9 | Sequence Analysis, DNA (MeSH) |
| 9 | Respiratory Tract Infections (diagnosis) |
| 9 | Registries (MeSH) |
| 9 | RNA, Viral (genetics) |
| 9 | Poultry Diseases (prevention & control) |
| 9 | Orthomyxoviridae Infections (veterinary) |
| 9 | Orthomyxoviridae Infections (transmission) |
| 9 | Longitudinal Studies (MeSH) |
| 9 | Influenza A Virus, H7N7 Subtype (pathogenicity) |
| 9 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
| 9 | Influenza A Virus, H5N1 Subtype (MeSH) |
| 9 | Influenza A Virus, H1N1 Subtype (genetics) |
| 9 | Health Surveys (MeSH) |
| 9 | Computer Simulation (MeSH) |
| 9 | Animals, Wild (virology) |
| 8 | Zoonoses (transmission) |
| 8 | Practice Patterns, Physicians' (MeSH) |
| 8 | Pneumococcal Infections (prevention & control) |
| 8 | Mortality (trends) |
| 8 | Models, Economic (MeSH) |
| 8 | Influenza, Human (etiology) |
| 8 | Influenza A Virus, H7N7 Subtype (genetics) |
| 8 | Hospitalization (MeSH) |
| 8 | Global Health (MeSH) |
| 8 | Epidemics (MeSH) |
| 8 | Diagnosis, Differential (MeSH) |
| 7 | Virus Diseases (epidemiology) |
| 7 | Vaccination (methods) |
| 7 | Vaccination (adverse effects) |
| 7 | Turkeys (MeSH) |
| 7 | Respiratory Tract Diseases (epidemiology) |
| 7 | Respiratory Syncytial Virus Infections (epidemiology) |
| 7 | Reproducibility of Results (MeSH) |
| 7 | Qualitative Research (MeSH) |
| 7 | Poultry Diseases (transmission) |
| 7 | Poultry (virology) |
| 7 | Patient Acceptance of Health Care (MeSH) |
| 7 | Oseltamivir (MeSH) |
| 7 | Orthomyxoviridae (immunology) |
| 7 | Orthomyxoviridae (classification) |
| 7 | Multivariate Analysis (MeSH) |
| 7 | Molecular Sequence Data (MeSH) |
| 7 | Italy (epidemiology) |
| 7 | Influenza A virus (physiology) |
| 7 | Influenza A Virus, H5N8 Subtype (pathogenicity) |
| 7 | Influenza A Virus, H5N8 Subtype (genetics) |
| 7 | Influenza A Virus, H5N1 Subtype (genetics) |
| 7 | Influenza A Virus, H3N2 Subtype (MeSH) |
| 7 | Immunization Programs (statistics & numerical data) |
| 7 | History, 21st Century (MeSH) |
| 7 | Health Policy (MeSH) |
| 7 | Europe (epidemiology) |
| 7 | Enzyme-Linked Immunosorbent Assay (veterinary) |
| 7 | Communicable Diseases (epidemiology) |
| 7 | Communicable Disease Control (methods) |
| 7 | Cardiovascular Diseases (mortality) |
| 7 | Antiviral Agents (pharmacology) |
| 7 | Acetamides (therapeutic use) |
| 6 | Zoonoses (virology) |
| 6 | Virus Shedding (MeSH) |
| 6 | Virulence (MeSH) |
| 6 | Temperature (MeSH) |
| 6 | Swine Diseases (virology) |
| 6 | Societies, Medical (MeSH) |
| 6 | Reassortant Viruses (genetics) |
| 6 | Real-Time Polymerase Chain Reaction (MeSH) |
| 6 | Primary Health Care (MeSH) |
| 6 | Poultry Diseases (pathology) |
| 6 | Poisson Distribution (MeSH) |
| 6 | Pneumococcal Vaccines (administration & dosage) |
| 6 | Influenza, Human (history) |
| 6 | Influenza, Human (MeSH) |
| 6 | Ferrets (MeSH) |
| 6 | Fatal Outcome (MeSH) |
| 6 | Ducks (MeSH) |
| 6 | Disease Transmission, Infectious (prevention & control) |
| 6 | Cluster Analysis (MeSH) |
| 6 | Belgium (epidemiology) |
| 6 | Antibodies (MeSH) |
| 6 | Animals, Wild (MeSH) |
| 6 | Absenteeism (MeSH) |
| 5 | Virus Diseases (virology) |
| 5 | Virus Diseases (diagnosis) |
| 5 | Viral Proteins (genetics) |
| 5 | Vaccination (veterinary) |
| 5 | Swine Diseases (epidemiology) |
| 5 | Socioeconomic Factors (MeSH) |
| 5 | Sex Factors (MeSH) |
| 5 | Serotyping (MeSH) |
| 5 | Sentinel Surveillance (veterinary) |
| 5 | Security Measures (MeSH) |
| 5 | Schizophrenia (epidemiology) |
| 5 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 5 | Respiratory Tract Infections (microbiology) |
| 5 | Quality-Adjusted Life Years (MeSH) |
| 5 | Program Evaluation (MeSH) |
| 5 | Prognosis (MeSH) |
| 5 | Primary Prevention (MeSH) |
| 5 | Prenatal Exposure Delayed Effects (MeSH) |
| 5 | Predictive Value of Tests (MeSH) |
| 5 | Population Dynamics (MeSH) |
| 5 | Pneumococcal Infections (epidemiology) |
| 5 | Patient Acceptance of Health Care (statistics & numerical data) |
| 5 | Pandemics (statistics & numerical data) |
| 5 | Neuraminidase (genetics) |
| 5 | National Health Programs (MeSH) |
| 5 | Mutation (MeSH) |
| 5 | Mass Vaccination (MeSH) |
| 5 | Interviews as Topic (MeSH) |
| 5 | Influenza, Human (therapy) |
| 5 | Influenza, Human (pathology) |
| 5 | Influenza A Virus, H5N8 Subtype (isolation & purification) |
| 5 | Influenza A Virus, H5N1 Subtype (isolation & purification) |
| 5 | Influenza A Virus, H3N2 Subtype (isolation & purification) |
| 5 | History, 20th Century (MeSH) |
| 5 | Health Care Surveys (MeSH) |
| 5 | Health Behavior (MeSH) |
| 5 | Genetic Variation (MeSH) |
| 5 | General Practitioners (statistics & numerical data) |
| 5 | Forecasting (MeSH) |
| 5 | Follow-Up Studies (MeSH) |
| 5 | Family Practice (statistics & numerical data) |
| 5 | Europe (MeSH) |
| 5 | England (epidemiology) |
| 5 | Double-Blind Method (MeSH) |
| 5 | Disease Outbreaks (economics) |
| 5 | Demography (MeSH) |
| 5 | Decision Making (MeSH) |
| 5 | Databases, Factual (MeSH) |
| 5 | Confidence Intervals (MeSH) |
| 5 | Belgium (MeSH) |
| 5 | Attitude to Health (MeSH) |
| 5 | Asia (epidemiology) |
| 5 | Antiviral Agents (economics) |
| 5 | Antibodies, Viral (immunology) |
| 5 | Analysis of Variance (MeSH) |
| 5 | Air Pollution (adverse effects) |
| 5 | Adverse Drug Reaction Reporting Systems (MeSH) |
| 5 | Acute Disease (MeSH) |
| 4 | Zoonoses (epidemiology) |
| 4 | World Health Organization (MeSH) |
| 4 | Workforce (MeSH) |
| 4 | Wind (MeSH) |
| 4 | Wales (epidemiology) |
| 4 | Turkeys (virology) |
| 4 | Travel (MeSH) |
| 4 | Switzerland (epidemiology) |
| 4 | Schizophrenia (etiology) |
| 4 | Risk Assessment (methods) |
| 4 | Reverse Transcriptase Polymerase Chain Reaction (veterinary) |
| 4 | Respiratory Tract Diseases (mortality) |
| 4 | Reassortant Viruses (isolation & purification) |
| 4 | Quality Control (MeSH) |
| 4 | Publishing (MeSH) |
| 4 | Public Opinion (MeSH) |
| 4 | Polymerase Chain Reaction (methods) |
| 4 | Pneumonia (epidemiology) |
| 4 | Pneumococcal Vaccines (therapeutic use) |
| 4 | Pilot Projects (MeSH) |
| 4 | Patient Education as Topic (MeSH) |
| 4 | Patient Compliance (MeSH) |
| 4 | Outcome Assessment, Health Care (MeSH) |
| 4 | Occupational Exposure (MeSH) |
| 4 | Neuraminidase (antagonists & inhibitors) |
| 4 | Morbidity (MeSH) |
| 4 | Linear Models (MeSH) |
| 4 | Likelihood Functions (MeSH) |
| 4 | Intention (MeSH) |
| 4 | Influenza in Birds (immunology) |
| 4 | Influenza A virus (drug effects) |
| 4 | Influenza A Virus, H7N7 Subtype (isolation & purification) |
| 4 | Influenza A Virus, H5N8 Subtype (classification) |
| 4 | Influenza A Virus, H3N2 Subtype (immunology) |
| 4 | Influenza A Virus, H1N1 Subtype (physiology) |
| 4 | Influenza A Virus, H1N1 Subtype (drug effects) |
| 4 | Immunization Programs (economics) |
| 4 | Hospitals (MeSH) |
| 4 | Horses (MeSH) |
| 4 | Homes for the Aged (MeSH) |
| 4 | History, 19th Century (MeSH) |
| 4 | Health Personnel (statistics & numerical data) |
| 4 | Guidelines as Topic (MeSH) |
| 4 | Germany (MeSH) |
| 4 | General Practitioners (psychology) |
| 4 | Gastroenteritis (epidemiology) |
| 4 | Focus Groups (MeSH) |
| 4 | European Union (MeSH) |
| 4 | Epidemics (veterinary) |
| 4 | Epidemics (statistics & numerical data) |
| 4 | Enzyme-Linked Immunosorbent Assay (methods) |
| 4 | Environmental Exposure (adverse effects) |
| 4 | Ducks (virology) |
| 4 | Drug-Related Side Effects and Adverse Reactions (epidemiology) |
| 4 | Drug Resistance, Viral (MeSH) |
| 4 | Disease Outbreaks (history) |
| 4 | Disaster Planning (MeSH) |
| 4 | Data Collection (MeSH) |
| 4 | Cross Infection (prevention & control) |
| 4 | Cross Infection (epidemiology) |
| 4 | Comorbidity (MeSH) |
| 4 | Community-Acquired Infections (microbiology) |
| 4 | Communicable Diseases, Emerging (epidemiology) |
| 4 | Communicable Disease Control (MeSH) |
| 4 | Chronic Disease (MeSH) |
| 4 | China (epidemiology) |
| 4 | Chick Embryo (MeSH) |
| 4 | Cell Line (MeSH) |
| 4 | Bird Diseases (epidemiology) |
| 4 | Bayes Theorem (MeSH) |
| 4 | Antiviral Agents (administration & dosage) |
| 4 | Antigens, Viral (analysis) |
| 4 | Anti-Bacterial Agents (therapeutic use) |
| 4 | Air Pollutants (analysis) |
| 4 | Academic Medical Centers (MeSH) |
| 3 | Workload (MeSH) |
| 3 | Weather (MeSH) |
| 3 | Viruses (isolation & purification) |
| 3 | Viral Proteins (metabolism) |
| 3 | Viral Load (MeSH) |
| 3 | Veterinarians (MeSH) |
| 3 | Vaccination (trends) |
| 3 | Vaccination (standards) |
| 3 | Syndrome (MeSH) |
| 3 | Swine Diseases (transmission) |
| 3 | Sweden (epidemiology) |
| 3 | Sweden (MeSH) |
| 3 | Sulfur Dioxide (analysis) |
| 3 | Sulfur Dioxide (adverse effects) |
| 3 | Streptococcus pneumoniae (isolation & purification) |
| 3 | Stochastic Processes (MeSH) |
| 3 | Statistics as Topic (MeSH) |
| 3 | Species Specificity (MeSH) |
| 3 | Severe Acute Respiratory Syndrome (prevention & control) |
| 3 | Serologic Tests (MeSH) |
| 3 | Self Report (MeSH) |
| 3 | Schools (MeSH) |
| 3 | Salmonella Infections (epidemiology) |
| 3 | Respiratory Syncytial Virus Infections (virology) |
| 3 | Residence Characteristics (MeSH) |
| 3 | Research Design (MeSH) |
| 3 | Registries (statistics & numerical data) |
| 3 | Recurrence (MeSH) |
| 3 | Reassortant Viruses (pathogenicity) |
| 3 | RNA Replicase (genetics) |
| 3 | Primary Health Care (statistics & numerical data) |
| 3 | Pregnancy Trimester, Second (MeSH) |
| 3 | Pregnancy Outcome (MeSH) |
| 3 | Pregnancy Complications, Infectious (virology) |
| 3 | Pregnancy Complications, Infectious (prevention & control) |
| 3 | Practice Patterns, Physicians' (statistics & numerical data) |
| 3 | Poultry Diseases (diagnosis) |
| 3 | Population (MeSH) |
| 3 | Polymerase Chain Reaction (MeSH) |
| 3 | Pneumonia, Viral (epidemiology) |
| 3 | Pneumonia (mortality) |
| 3 | Pharmacovigilance (MeSH) |
| 3 | Parents (MeSH) |
| 3 | Paramyxoviridae Infections (epidemiology) |
| 3 | Oseltamivir (economics) |
| 3 | Oseltamivir (administration & dosage) |
| 3 | Orthomyxoviridae (pathogenicity) |
| 3 | Orthomyxoviridae (genetics) |
| 3 | Occupational Diseases (prevention & control) |
| 3 | Occupational Diseases (epidemiology) |
| 3 | Norway (epidemiology) |
| 3 | Needs Assessment (MeSH) |
| 3 | National Health Programs (organization & administration) |
| 3 | Nasopharynx (virology) |
| 3 | Motivation (MeSH) |
| 3 | Monte Carlo Method (MeSH) |
| 3 | Meat (virology) |
| 3 | Mass Media (MeSH) |
| 3 | Markov Chains (MeSH) |
| 3 | Lung Diseases (complications) |
| 3 | Lung (virology) |
| 3 | Length of Stay (MeSH) |
| 3 | Laboratories (MeSH) |
| 3 | Japan (MeSH) |
| 3 | International Cooperation (MeSH) |
| 3 | Intensive Care Units, Pediatric (MeSH) |
| 3 | Information Dissemination (MeSH) |
| 3 | Influenza, Human (veterinary) |
| 3 | Influenza, Human (ethnology) |
| 3 | Influenza in Birds (psychology) |
| 3 | Influenza Vaccines (supply & distribution) |
| 3 | Influenza B virus (pathogenicity) |
| 3 | Influenza B virus (genetics) |
| 3 | Influenza B virus (drug effects) |
| 3 | Influenza A Virus, H5N1 Subtype (immunology) |
| 3 | Influenza A Virus, H3N2 Subtype (genetics) |
| 3 | Immunization, Secondary (methods) |
| 3 | Immunization Schedule (MeSH) |
| 3 | Immunization Programs (organization & administration) |
| 3 | Immunization Programs (methods) |
| 3 | Hygiene (MeSH) |
| 3 | Hospitalization (economics) |
| 3 | Herpes Zoster (epidemiology) |
| 3 | Hepatitis B (prevention & control) |
| 3 | Hemagglutinin Glycoproteins, Influenza Virus (metabolism) |
| 3 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
| 3 | Hemagglutinin Glycoproteins, Influenza Virus (chemistry) |
| 3 | Hemagglutination Inhibition Tests (veterinary) |
| 3 | Hemagglutination Inhibition Tests (methods) |
| 3 | Health Personnel (psychology) |
| 3 | Health Care Costs (MeSH) |
| 3 | Guideline Adherence (statistics & numerical data) |
| 3 | France (epidemiology) |
| 3 | Feasibility Studies (MeSH) |
| 3 | Family Practice (standards) |
| 3 | Family Characteristics (MeSH) |
| 3 | Epidemiological Monitoring (MeSH) |
| 3 | Epidemiologic Studies (MeSH) |
| 3 | Epidemiologic Methods (MeSH) |
| 3 | Enzyme Inhibitors (therapeutic use) |
| 3 | Drug Prescriptions (statistics & numerical data) |
| 3 | Disease Transmission, Infectious (statistics & numerical data) |
| 3 | Disease Susceptibility (epidemiology) |
| 3 | Disease (MeSH) |
| 3 | Developed Countries (MeSH) |
| 3 | Denmark (epidemiology) |
| 3 | Cough (epidemiology) |
| 3 | Conjunctivitis, Viral (virology) |
| 3 | Conjunctivitis, Viral (epidemiology) |
| 3 | Confounding Factors, Epidemiologic (MeSH) |
| 3 | Complement Fixation Tests (MeSH) |
| 3 | Clinical Trials as Topic (MeSH) |
| 3 | Classical Swine Fever (epidemiology) |
| 3 | Choice Behavior (MeSH) |
| 3 | Charadriiformes (MeSH) |
| 3 | Cause of Death (trends) |
| 3 | Biomedical Research (methods) |
| 3 | Bacterial Infections (epidemiology) |
| 3 | Asthma (complications) |
| 3 | Antigens, Viral (immunology) |
| 3 | Antibodies, Viral (isolation & purification) |
| 3 | Antibodies, Viral (analysis) |
| 3 | Amino Acid Substitution (MeSH) |
| 3 | Air Pollution (analysis) |
| 3 | Air Pollutants (adverse effects) |
| 3 | Aging (MeSH) |
| 3 | Advisory Committees (MeSH) |
| 3 | Adjuvants, Immunologic (MeSH) |
| 2 | Zanamivir (therapeutic use) |
| 2 | Zanamivir (MeSH) |
| 2 | Whooping Cough (epidemiology) |
| 2 | Whole Genome Sequencing (MeSH) |
| 2 | Virus Replication (MeSH) |
| 2 | Virus Diseases (veterinary) |
| 2 | Virus Diseases (complications) |
| 2 | Virus Diseases (MeSH) |
| 2 | Veterinarians (psychology) |
| 2 | Vehicle Emissions (adverse effects) |
| 2 | Vaccines, Conjugate (MeSH) |
| 2 | Vaccines (adverse effects) |
| 2 | United States (epidemiology) |
| 2 | United Kingdom (MeSH) |
| 2 | Trust (MeSH) |
| 2 | Treatment Refusal (MeSH) |
| 2 | Tetanus Toxoid (therapeutic use) |
| 2 | Tetanus Toxoid (MeSH) |
| 2 | Tetanus (prevention & control) |
| 2 | Tertiary Care Centers (MeSH) |
| 2 | T-Lymphocytes (immunology) |
| 2 | Swine Diseases (prevention & control) |
| 2 | Swine Diseases (immunology) |
| 2 | Swine (virology) |
| 2 | Swine (microbiology) |
| 2 | Survival Rate (MeSH) |
| 2 | Survival Analysis (MeSH) |
